Johnson & Johnson (JNJ)
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Worried About a Stock Market Crash: Buy These 2 Stocks Now
If you're just a bit more worried about a market sell-off going into the fourth quarter, you're not alone.
2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem
Dividend cuts and suspensions can come suddenly and investors should always be on the lookout for warning signs. A strong track record for dividend growth is by no means a guarantee that a company will pay and increase its dividend in the future.
Johnson & Johnson wins over longtime holdout for talc settlement, WSJ reports
Johnson & Johnson is expected to secure more votes in favor of its talc settlement plan after increasing its offer to claimants, which has swayed a longtime legal adversary, WSJ reported on Wednesday, citing people familiar with the matter.
Johnson & Johnson (JNJ) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 10:45 AM ET Company Participants Joaquin Duato - CEO & Chairman John Reed - Head of Pharma R&D Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. All right.
3 Dividend Stocks to Double Up on Right Now
Verizon offers a high-yielding and steadily rising dividend. Johnson & Johnson pays a very healthy dividend.
Johnson & Johnson (JNJ) Increases Despite Market Slip: Here's What You Need to Know
Johnson & Johnson (JNJ) concluded the recent trading session at $167.16, signifying a +0.78% move from its prior day's close.
Is Johnson & Johnson the Best Dividend Stock for You?
Johnson & Johnson is a remarkably consistent business. A fortress-like balance sheet all but guarantees the dividend's safety.
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
Must-have stocks for passive income in 2025
In addition to profiting from ordinary trading activities, the stock market offers opportunities for investors seeking passive income through dividend payouts.
Drop Johnson & Johnson, Pick These Steady Eddie Stocks?
If you are a Johnson & Johnson investor and have been enjoying the stock's steady dividends, it may be time to look elsewhere. As of this moment, we find DaVita - a healthcare company focused on kidney dialysis services - and Duke Energy - an electric and natural gas utility company based in North Carolina - as more attractive buys than Johnson & Johnson.
Johnson & Johnson's Golden Cross: A Bullish Prescription For Investors?
Johnson & Johnson JNJ has just made a significant technical move, achieving a Golden Cross.
